JP2020529400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529400A5 JP2020529400A5 JP2020504128A JP2020504128A JP2020529400A5 JP 2020529400 A5 JP2020529400 A5 JP 2020529400A5 JP 2020504128 A JP2020504128 A JP 2020504128A JP 2020504128 A JP2020504128 A JP 2020504128A JP 2020529400 A5 JP2020529400 A5 JP 2020529400A5
- Authority
- JP
- Japan
- Prior art keywords
- coor
- alkyl
- halogen
- amino
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052736 halogen Inorganic materials 0.000 claims 219
- 150000002367 halogens Chemical class 0.000 claims 219
- 125000000217 alkyl group Chemical group 0.000 claims 210
- 229910052799 carbon Inorganic materials 0.000 claims 70
- 229910052739 hydrogen Inorganic materials 0.000 claims 70
- 150000001875 compounds Chemical class 0.000 claims 50
- 150000003839 salts Chemical class 0.000 claims 48
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 35
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 35
- 229910052757 nitrogen Inorganic materials 0.000 claims 35
- 229910052760 oxygen Inorganic materials 0.000 claims 33
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 32
- 125000001424 substituent group Chemical group 0.000 claims 32
- -1 6-amino-9H-purine-9-yl Chemical group 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- HNIKXHIFOPQCRB-UHFFFAOYSA-N CCC(CCCCCCCCC(CCCCCC)=S)=S Chemical compound CCC(CCCCCCCCC(CCCCCC)=S)=S HNIKXHIFOPQCRB-UHFFFAOYSA-N 0.000 claims 7
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- WYCJWOAQAMWVLL-UHFFFAOYSA-N octadecane-3,12-dione Chemical compound CCC(CCCCCCCCC(CCCCCC)=O)=O WYCJWOAQAMWVLL-UHFFFAOYSA-N 0.000 claims 4
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940038384 octadecane Drugs 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 claims 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 claims 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- OSXKHFTZRHDUJN-UHFFFAOYSA-N N(2),3-ethenoguanine Chemical compound O=C1NC2=NC=CN2C2=C1NC=N2 OSXKHFTZRHDUJN-UHFFFAOYSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000000107 disulfanyl group Chemical group [*]SS[H] 0.000 claims 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- HHQOJAVJSCPMAC-UHFFFAOYSA-N octadecan-7-one Chemical compound CCCCCCCCCCCC(=O)CCCCCC HHQOJAVJSCPMAC-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 0 C*C1=C(C(NC(*)=N)=O)N=N*1C Chemical compound C*C1=C(C(NC(*)=N)=O)N=N*1C 0.000 description 10
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538329P | 2017-07-28 | 2017-07-28 | |
| US62/538,329 | 2017-07-28 | ||
| PCT/US2018/043907 WO2019023459A1 (en) | 2017-07-28 | 2018-07-26 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529400A JP2020529400A (ja) | 2020-10-08 |
| JP2020529400A5 true JP2020529400A5 (enExample) | 2021-08-19 |
| JP7186764B2 JP7186764B2 (ja) | 2022-12-09 |
Family
ID=63165538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504128A Active JP7186764B2 (ja) | 2017-07-28 | 2018-07-26 | 抗癌剤としての環状ジヌクレオチド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10744150B2 (enExample) |
| EP (1) | EP3658565B1 (enExample) |
| JP (1) | JP7186764B2 (enExample) |
| KR (1) | KR102709265B1 (enExample) |
| CN (1) | CN110997691B (enExample) |
| AR (1) | AR112290A1 (enExample) |
| ES (1) | ES2932354T3 (enExample) |
| TW (1) | TW201909903A (enExample) |
| WO (1) | WO2019023459A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| SG11202008827XA (en) | 2018-04-13 | 2020-10-29 | Bristol Myers Squibb Co | Novel phosphorous (v)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (v) compounds |
| CN110818714A (zh) * | 2018-08-14 | 2020-02-21 | 连云港润众制药有限公司 | 一种恩替卡韦中间体的合成方法 |
| US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| US12421268B2 (en) | 2019-04-16 | 2025-09-23 | Roche Innovation Center Copenhagen A/S | Process for preparing nucleotide P(V) monomers |
| JP7621974B2 (ja) | 2019-05-09 | 2025-01-27 | アリゴス セラピューティクス インコーポレイテッド | Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物 |
| WO2021013234A1 (en) | 2019-07-25 | 2021-01-28 | Beigene, Ltd. | Cyclic dinucleotides as sting agonists |
| CN110684062B (zh) * | 2019-10-18 | 2022-12-13 | 大连大学 | 一种治疗非小细胞肺癌的药物及其制备方法 |
| JPWO2021206158A1 (enExample) | 2020-04-10 | 2021-10-14 | ||
| CN119930724B (zh) * | 2024-12-18 | 2025-10-28 | 湖南大学 | 一种诱导激活的自递送环二核苷衍生物及其制备方法与用于抗肿瘤免疫治疗的用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1611249A4 (en) | 2003-03-31 | 2006-06-28 | Isis Pharmaceuticals Inc | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR RNA CLEAVAGE |
| AU2005222626B2 (en) * | 2004-03-15 | 2010-05-20 | Karagen Pharmaceuticals, Inc. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| DK2559690T3 (en) | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
| US7575764B2 (en) * | 2005-10-01 | 2009-08-18 | Elc Management Llc | Compositions comprising hypsizygus ulmarius extract |
| EP1782826A1 (en) * | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CN103951753B (zh) | 2009-09-03 | 2018-01-12 | 默沙东公司 | 抗‑gitr抗体 |
| ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
| CN105218672A (zh) | 2009-12-10 | 2016-01-06 | 霍夫曼-拉罗奇有限公司 | 优先结合人csf1r胞外域4的抗体及其用途 |
| ME03447B (me) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| KR20200044999A (ko) | 2010-05-04 | 2020-04-29 | 파이브 프라임 테라퓨틱스, 인크. | Ｃｓｆ1ｒ에 결합하는 항체들 |
| CN105481983B (zh) | 2010-09-09 | 2021-09-03 | 辉瑞公司 | 4-1bb结合分子 |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| JP6416630B2 (ja) | 2012-02-06 | 2018-10-31 | ジェネンテック， インコーポレイテッド | Ｃｓｆ１ｒ阻害剤を用いるための組成物及び方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2013181634A2 (en) | 2012-05-31 | 2013-12-05 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| TWI713436B (zh) | 2012-08-31 | 2020-12-21 | 美商戊瑞治療有限公司 | 用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| CU24377B1 (es) * | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| CA2913977C (en) | 2013-05-31 | 2022-11-29 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| HRP20221262T1 (hr) | 2013-09-13 | 2022-12-09 | Beigene Switzerland Gmbh | Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava |
| SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| KR20170015353A (ko) * | 2014-06-04 | 2017-02-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Ｓｔｉｎｇ의 조절제로서 사이클릭 디뉴클레오타이드 |
| CN107148424B (zh) | 2014-12-16 | 2021-01-08 | 凯拉治疗股份公司 | 用于诱导细胞因子的环状二核苷酸 |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
-
2018
- 2018-07-26 KR KR1020207005451A patent/KR102709265B1/ko active Active
- 2018-07-26 CN CN201880049466.7A patent/CN110997691B/zh active Active
- 2018-07-26 EP EP18752985.4A patent/EP3658565B1/en active Active
- 2018-07-26 JP JP2020504128A patent/JP7186764B2/ja active Active
- 2018-07-26 ES ES18752985T patent/ES2932354T3/es active Active
- 2018-07-26 WO PCT/US2018/043907 patent/WO2019023459A1/en not_active Ceased
- 2018-07-27 TW TW107126128A patent/TW201909903A/zh unknown
- 2018-07-27 US US16/047,071 patent/US10744150B2/en active Active
- 2018-07-27 AR ARP180102134 patent/AR112290A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529400A5 (enExample) | ||
| JP2020536897A5 (enExample) | ||
| JP2020532542A5 (enExample) | ||
| JP2020536971A5 (enExample) | ||
| ES2430053T3 (es) | Procedimiento para producir derivados de bicicloanilina | |
| JP2020532529A5 (enExample) | ||
| US11090306B2 (en) | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | |
| HRP20220520T1 (hr) | Ciklički dinukleotidi kao agensi protiv raka | |
| JP2020532539A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| JP2013519707A5 (enExample) | ||
| KR20100024932A (ko) | 비사이클로아닐린 유도체 | |
| UA121492C2 (uk) | Біциклічні гетероцикли як інгібітори fgfr4 | |
| JP2014513704A5 (enExample) | ||
| AU2009271419B2 (en) | Antineoplastic combinations containing HKI-272 and vinorelbine | |
| US20020183239A1 (en) | Antineoplastic combinations | |
| CN110167941A (zh) | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 | |
| RU2015126795A (ru) | Минующие нуклеозид киназу композиции и способы их получения и применения | |
| JP2014510080A5 (enExample) | ||
| KR20100017984A (ko) | 7-(2,5-디히드로-4-이미다조[1,2-ａ]피리딘-3-일-2,5-디옥소-1ｈ-피롤-3-일)-9-플루오로-1,2,3,4-테트라히드로-2-(1-피페리디닐카르보닐)-피롤로[3,2,1-ｊｋ][1,4]벤조디아제핀에 의한 암 화학요법의 강화 | |
| MX2014009991A (es) | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. | |
| KR20160030239A (ko) | 치환된 피라졸로-피리딘아민 | |
| RU2013120357A (ru) | Фармацевтические комбинации | |
| JPWO2020032105A5 (enExample) | ||
| WO2014157444A1 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 |